Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 665
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
J Eur Acad Dermatol Venereol ; 34(3): 447-454, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31898355

RESUMEN

The use of sunscreens is an important and essential component of photoprotection. Since their introduction during the first half of the last century, sunscreens have benefited enormously from major technological advances such as the development of novel UV filters; as a result, their efficacy in preventing UV-induced erythema is unequivocal. More recently, however, new challenges have appeared, which have prompted a robust discussion about the safety of sunscreens. These include topics directly related to photoprotection of human skin such as improved/alternative methods for standardization of assessment of the efficacy of sunscreens, but also many others such as photoprotection beyond UV, concerns about human toxicity and ecological safety, the potential of oral photoprotective measures, consequences of innovative galenic formulations. On a first glance, some of these might raise questions and doubts among dermatologists, physicians and the general public about the use sunscreens as a means of photoprotection. This situation has prompted us to critically review such challenges, but also opportunities, based on existing scientific evidence. We conclude by providing our vision about how such challenges can be met best in the future in an attempt to create the ideal sunscreen, which should provide adequate and balanced protection and be easy and safe to use.


Asunto(s)
Eritema/prevención & control , Neoplasias Cutáneas/prevención & control , Protectores Solares/uso terapéutico , Eritema/etiología , Predicción , Humanos , Guías de Práctica Clínica como Asunto , Neoplasias Cutáneas/etiología , Rayos Ultravioleta/efectos adversos
2.
J Eur Acad Dermatol Venereol ; 33(4): 718-724, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30468530

RESUMEN

BACKGROUND: The current evidences attest UVA1 phototherapy as effective in the treatment of severe atopic dermatitis (AD). Furthermore, in this indication, 'medium dose' is as effective as 'high dose' regimen. To date, a randomized comparison study evaluating the effectiveness as well as safety of different UVA1 protocols in different skin types in the treatment of adult patients with severe AD is still lacking. OBJECTIVE: The aim of the present study was to compare the safety and the efficacy of medium and high dose UVA1 either in fair or in dark skin types. METHODS: Twenty-seven adult patients with severe AD were consecutively included in a randomized, controlled, open, two arms trial Severity of AD was determined by means of SCORAD index and clinical improvement was also monitored. A total of 13 out of 27 patients were treated with high dose (130 J/cm2 ) UVA1 protocol while 14 out of 27 patients received medium dose (60 J/cm2 ) UVA1 protocol. Phototherapy was performed five times weekly up to 3 weeks. Before and after UVA1 treatment each patient was evaluated for skin pigmentation through Melanin Index (MI) quantitative evaluation. RESULTS: Skin status improved in all patients resulting in a reduction of SCORAD index in all groups. Our results demonstrated that among patients with darker skin types and higher MI, high dose UVA1 was significantly more effective than medium dose (P < 0.0001) while within the groups with skin type II, no significant differences between high and medium dose protocols were observed. CONCLUSION: Our study, confirms previous observations that UVA1 phototherapy should be considered among the first approaches in the treatment of patients with severe generalized AD and also demonstrates that in darker skin types, high dose UVA1 phototherapy is more effective than medium dose in the treatment of adult patients with severe AD.


Asunto(s)
Dermatitis Atópica/radioterapia , Pigmentación de la Piel , Terapia Ultravioleta/métodos , Adulto , Femenino , Humanos , Italia , Masculino , Persona de Mediana Edad , Dosificación Radioterapéutica , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Terapia Ultravioleta/efectos adversos , Adulto Joven
3.
Ann Oncol ; 29(12): 2288-2295, 2018 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-30304498

RESUMEN

Quality of life (QoL) is a relevant end point and a topic of growing interest by both scientific community and regulatory authorities. Our aim was to review QoL prevalence as an end point in cancer phase III trials published in major journals and to evaluate QoL reporting deficiencies in terms of under-reporting and delay of publication. All issues published between 2012 and 2016 by 11 major journals were hand-searched for primary publications of phase III trials in adult patients with solid tumors. Information about end points was derived from paper and study protocol, when available. Secondary QoL publications were searched in PubMed. In total, 446 publications were eligible. In 210 (47.1%), QoL was not included among end points. QoL was not an end point in 40.1% of trials in the advanced/metastatic setting, 39.7% of profit trials and 53.6% of non-profit trials. Out of 231 primary publications of trials with QoL as secondary or exploratory end point, QoL results were available in 143 (61.9%). QoL results were absent in 37.6% of publications in the advanced/metastatic setting, in 37.1% of profit trials and 39.3% of non-profit trials. Proportion of trials not including QoL as end point or with missing QoL results was relevant in all tumor types and for all treatment types. Overall, 70 secondary QoL publications were found: for trials without QoL results in the primary publication, probability of secondary publication was 12.5%, 30.9% and 40.3% at 1, 2 and 3 years, respectively. Proportion of trials not reporting QoL results was similar in trials with positive results (36.5%) and with negative results (39.4%), but the probability of secondary publication was higher in positive trials. QoL is not included among end points in a relevant proportion of recently published phase III trials in solid tumors. In addition, QoL results are subject to significant under-reporting and delay in publication.


Asunto(s)
Ensayos Clínicos Fase III como Asunto/normas , Oncología Médica/normas , Neoplasias/terapia , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto/normas , Humanos , Neoplasias/mortalidad , Neoplasias/psicología , Medición de Resultados Informados por el Paciente , Guías de Práctica Clínica como Asunto , Supervivencia sin Progresión , Proyectos de Investigación/normas
4.
Breast Cancer Res Treat ; 169(3): 457-467, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29464534

RESUMEN

PURPOSE: High expression of glioma-associated oncogene homolog-1 (GLI1) is associated with poor prognosis in estrogen receptor (ER) positive breast cancers. We sought to define a GLI1-dependent gene signature in ER-positive tumors that could further stratify patients at higher risk for disease recurrence and potentially lead to novel combination therapies. METHODS: We identified an inverse correlation between GLI1 expression and distant disease-free survival (DFS) using a dataset developed at MD Anderson Cancer Center (Hatzis dataset) containing clinical data from 508 breast cancer patients. Using a qPCR-based microarray platform, we identified genes differentially regulated by GLI1 in MCF7 cells and then determined if expression of these genes correlated with GLI1 expression in patient tumor samples. Statistical comparison between the groups was performed by ANOVA. Direct comparison of two groups was done by a two-tailed t test. Correlations between variables were done by Pearson's method. RESULTS: Expression of GLI1 and its target genes correlated significantly with worse distant DFS in breast cancer patients with Luminal A molecular subtype. Particularly, co-expression of GLI1 with EGFR and/or SNAI1, two of the identified GLI1 targets, was predictive of worse distant DFS in this subtype. Furthermore, patients with Luminal A tumors with a high GLI1 signature had a shorter distant DFS compared to the Luminal B subtype and the outcome for this group was comparable to patients with HER2-positive or basal-like tumors. CONCLUSION: We have identified a novel GLI1 gene signature that is associated with worse clinical outcomes among the patients with Luminal A subtype of breast cancer.


Asunto(s)
Neoplasias de la Mama/genética , Neoplasias de la Mama/metabolismo , Regulación Neoplásica de la Expresión Génica , Proteínas Hedgehog/metabolismo , Transducción de Señal , Adulto , Biomarcadores de Tumor , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/patología , Línea Celular Tumoral , Supervivencia Celular , Resistencia a Antineoplásicos , Expresión Génica Ectópica , Femenino , Perfilación de la Expresión Génica , Humanos , Persona de Mediana Edad , Clasificación del Tumor , Estadificación de Neoplasias , Pronóstico , Receptor ErbB-2/metabolismo , Receptores de Estrógenos/metabolismo , Análisis de Supervivencia , Transcriptoma , Proteína con Dedos de Zinc GLI1/genética , Proteína con Dedos de Zinc GLI1/metabolismo
5.
Ann Oncol ; 28(7): 1547-1553, 2017 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-28368509

RESUMEN

BACKGROUND: Allogeneic stem-cell transplantation (HSCT) is the only curative treatment in myelodysplastic syndromes (MDS). Azacitidine (AZA) is increasingly used prior to HSCT, however in Europe it is only approved for patients who are not eligible for HSCT. PATIENTS AND METHODS: We conducted a phase II multicenter study to prospectively evaluate the feasibility of HSCT after treatment with AZA in 70 patients with a myelodysplastic syndrome (MDS), 19 with acute myeloid leukemia (AML), and 8 with chronic myelomonocytic leukemia (CMML). After a median of four cycles (range 1-11): 24% of patients achieved complete remission, 14% partial remission, 8% hematologic improvement, 32% had stable and 22% progressive disease. Ten patients discontinued treatment before the planned four cycles, due to an adverse event in nine cases. RESULTS: A HSC donor was identified in 73 patients, and HSCT was performed in 54 patients (74% of patients with a donor). Main reasons for turning down HSCT were lack of a donor, an adverse event, or progressive disease (9, 12, and 16 patients, respectively). At a median follow-up of 20.5 months from enrolment, response to AZA was the only independent prognostic factor for survival. Compared to baseline assessment, AZA treatment did not affect patients' comorbidities at HSCT: the HCT-CI remained stable in 62% patients, and worsened or improved in 23% and 15% of patients, respectively. CONCLUSIONS: Our study shows that HSCT is feasible in the majority of patients with HR-MDS/AML/CMML-2 after AZA treatment. As matched unrelated donor was the most frequent source of donor cells, the time between diagnosis and HSCT needed for donor search could be 'bridged' using azacitidine. These data show that AZA prior to HSCT could be a better option than intensive chemotherapy in higher-risk MDS. The trial has been registered with the EudraCT number 2010-019673-1.


Asunto(s)
Antimetabolitos Antineoplásicos/administración & dosificación , Azacitidina/administración & dosificación , Trasplante de Células Madre Hematopoyéticas , Leucemia Mieloide Aguda/terapia , Leucemia Mielomonocítica Crónica/terapia , Síndromes Mielodisplásicos/terapia , Acondicionamiento Pretrasplante/métodos , Adulto , Anciano , Antimetabolitos Antineoplásicos/efectos adversos , Azacitidina/efectos adversos , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Esquema de Medicación , Estudios de Factibilidad , Femenino , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Trasplante de Células Madre Hematopoyéticas/mortalidad , Humanos , Italia , Leucemia Mieloide Aguda/mortalidad , Leucemia Mieloide Aguda/patología , Leucemia Mielomonocítica Crónica/mortalidad , Leucemia Mielomonocítica Crónica/patología , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/mortalidad , Síndromes Mielodisplásicos/patología , Estudios Prospectivos , Factores de Riesgo , Análisis de Supervivencia , Factores de Tiempo , Acondicionamiento Pretrasplante/efectos adversos , Acondicionamiento Pretrasplante/mortalidad , Trasplante Homólogo , Resultado del Tratamiento , Adulto Joven
6.
Eur Ann Allergy Clin Immunol ; 48(4): 156-60, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-27425174

RESUMEN

Given the increasing life expectancy observed in Western countries, there is a marked interest to know more about how aging could influence respiratory health. The aim of our study was to assess the prevalence, clinical characteristics and age of onset of allergic sensitization and clinical symptoms in a sample of atopic elders living in Campania region area (Southern Italy). Fourteen Allergy units or Centres examined a total of 462 patients. In this context 215 (46.53%) had positive skin prick tests (SPTs) to at least one allergen and were diagnosed with respiratory allergy. Parietaria represents the most common sensitizing agent in elders living in Campania region, followed by dust mites, grass pollen and Olea europaea. A relatively high percentage of atopic subjects suffered from respiratory symptoms at a fairly advanced age, namely 8.3% at 60-64 years, 10.2% at 65-70 and 5.7% at > 70 years. In conclusion, the prevalence and clinical significance of airway allergic sensitization in the elderly living in Campania region is more significant than expected in latter stages of life. Physicians should not neglect the role of atopy as a risk factor for the onset of allergic respiratory symptoms even in elderly patients.


Asunto(s)
Hipersensibilidad Respiratoria/epidemiología , Salud Urbana , Adulto , Distribución por Edad , Edad de Inicio , Anciano , Estudios Transversales , Humanos , Pruebas Intradérmicas , Italia/epidemiología , Persona de Mediana Edad , Prevalencia , Hipersensibilidad Respiratoria/diagnóstico , Factores de Riesgo
7.
Occup Med (Lond) ; 65(8): 632-7, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26503978

RESUMEN

BACKGROUND: Occupational diseases data can guide efforts to improve worker's health and safety. AIMS: To describe MALPROF, the Italian system for surveillance of work-related diseases collected by the subregional Department of Prevention. METHODS: The MALPROF system started in 1999 with contributions from Lombardy and Tuscany and spread in the following years to collect contributions from 14 out of the 20 Italian regions. MALPROF data were explored to follow-up work-related diseases and to detect emerging occupational health risks by calculating proportional reporting ratio (PRR), as in pharmacosurveillance. It classified work-related diseases according to economic sector and job activity in which the exposure occurred. Occupational physicians of the Italian National Health Service evaluate the possible causal relationship with occupational exposures and store the data in a centralized database. RESULTS: From 1999 to 2012, the MALPROF system collected about 112000 cases of workers' diseases. In 2010, more than 13000 cases of occupational diseases were reported. The most frequently reported diseases were hearing loss (n = 4378, 32%), spine disorders (n = 2394, 17%) and carpal tunnel syndrome (n = 1560, 11%). The PRR calculated for cervical disc herniation, a disease whose occupational origin has to be studied, in 1999-2010 was 2.47 [95% confidence interval (CI) 1.76-3.47] for drivers and 36.64 (95% CI 22.03-60.93) for air transport workers. CONCLUSIONS: MALPROF is a sensitive system for identifying possible associations between occupational risks and diseases, it can contribute to the development of preventive measures, to evaluate the effectiveness of preventive interventions and to stimulate research on new occupational risks and diseases.


Asunto(s)
Síndrome del Túnel Carpiano/epidemiología , Pérdida Auditiva/epidemiología , Enfermedades Musculoesqueléticas/epidemiología , Enfermedades Profesionales/epidemiología , Exposición Profesional/efectos adversos , Salud Laboral , Prevención Primaria/organización & administración , Traumatismos Vertebrales/epidemiología , Síndrome del Túnel Carpiano/prevención & control , Pérdida Auditiva/prevención & control , Humanos , Italia/epidemiología , Enfermedades Musculoesqueléticas/prevención & control , Programas Nacionales de Salud , Enfermedades Profesionales/prevención & control , Vigilancia de la Población , Regionalización , Administración de la Seguridad , Traumatismos Vertebrales/prevención & control , Indemnización para Trabajadores/estadística & datos numéricos
8.
Eur Ann Allergy Clin Immunol ; 46(1): 12-6, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24702867

RESUMEN

BACKGROUND: Although cockroach (CR) is an important cause of allergic sensitization worldwide, only a few data are available in Italy and in a previous study we have observed, in Naples area, a low prevalence of CR sensitization. OBJECTIVES: We sought to perform a prospective study for assessing the prevalence of allergic sensitization to CR in a sample of atopic population living in Campania district area (Southern Italy). METHODS: Ten Allergy Units or Centres of Campania district participated in this cross-sectional study. Each centre was required to collect the results of at least 100 allergy consultations in consecutive outpatients referred for actual or suspected respiratory allergy. We registered demographic data, type and duration of respiratory symptoms, pets ownership, possible exposure to CR allergens, results of the skin prick tests (SPTs). RESULTS: A total of 1477 patients were examined, 985 (66.68%) had a SPTs positivity to at least one allergen. In this context, ninety were sensitized to CR, thus the overall sensitization prevalence in subjects with respiratory allergy was 6.09% ranging between 0-11% and only five patients were mono-sensitized. Thirteen patients reported rhinitis (R) + bronchial asthma (A), twenty-one R + A + conjunctivitis (C), thirty-seven R + C, five only A and eleven individuals only R. Sixty-seven patients exhibited persistent and twenty-three intermittent symptoms. Dust mite constituted the first cause of associated sensitization to CR. CONCLUSIONS: The prevalence of allergic sensitization to CR is not negligible in population living in Campania district and shows a higher trend in comparison to that found recently and some years ago in Naples area. Finally, we suggest atopic individuals and especially those highly sensitized to mite allergens or those living in low-income areas to be tested by SPTs / evaluation of serum specific IgE to CR allergens to exclude the occurrence of CR allergic sensitization.


Asunto(s)
Alérgenos/inmunología , Cucarachas/inmunología , Hipersensibilidad/epidemiología , Adolescente , Adulto , Anciano , Animales , Niño , Preescolar , Femenino , Humanos , Italia/epidemiología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Salud Urbana
9.
Eur Rev Med Pharmacol Sci ; 28(9): 3293, 2024 05.
Artículo en Inglés | MEDLINE | ID: mdl-38766784

RESUMEN

The article "Autoantibodies detection in patients affected by autoimmune retinopathies", by M.R. Ceccarini, M.C. Medori, K. Dhuli, S. Tezzele, G. Bonetti, C. Micheletti, P.E. Maltese, S. Cecchin, K. Donato, L. Colombo, L. Rossetti, G. Staurenghi, A.P. Salvetti, M. Oldani, L. Ziccardi, D. Marangoni, G. Iarossi, B. Falsini, G. Placidi, F. D'Esposito, F. Viola, M. Nassisi, G. Leone, L. Cimino, L. De Simone, V. Mastrofilippo, T. Beccari, M. Bertelli, published in Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 57-63-DOI: 10.26355/eurrev_202312_34690-PMID: 38112948 has been retracted by the Editor in Chief for the following reasons. Following some concerns raised on PubPeer, the Editor in Chief has started an investigation to assess the validity of the results. The outcome of the investigation revealed that the manuscript presented major flaws in the following: -       Issues with ethical approval -       Undeclared conflict of interest In light of concerns regarding the potential manipulation of Supplementary Figure 2, the journal's inquiry has been unable to conclusively determine whether the alterations noted on PubPeer constitute figure manipulation. The investigation yielded divergent evaluations. However, given the aforementioned concerns, the Editor in Chief doubts the integrity of the findings presented and thus, has opted to retract the article. The authors disagree with this retraction. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/34690.


Asunto(s)
Autoanticuerpos , Enfermedades Autoinmunes , Humanos , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/diagnóstico , Enfermedades de la Retina/inmunología , Enfermedades de la Retina/diagnóstico , Retractación de Publicación como Asunto
10.
Br J Dermatol ; 168(1): 5-19, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22860621

RESUMEN

The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis and treatment. Up until now, treatment guidelines have existed at national levels, but no common European viewpoint has emerged. This guideline for the treatment of segmental and nonsegmental vitiligo has been developed by the members of the Vitiligo European Task Force and other colleagues. It summarizes evidence-based and expert-based recommendations (S1 level).


Asunto(s)
Vitíligo/terapia , Administración Cutánea , Administración Oral , Corticoesteroides/administración & dosificación , Antioxidantes/uso terapéutico , Inhibidores de la Calcineurina , Lista de Verificación , Terapia Combinada , Fármacos Dermatológicos/uso terapéutico , Humanos , Inmunosupresores/uso terapéutico , Fototerapia/métodos , Preparaciones para Aclaramiento de la Piel/uso terapéutico , Esteroides/administración & dosificación , Resultado del Tratamiento , Vitíligo/diagnóstico
11.
Eur Rev Med Pharmacol Sci ; 17(23): 3164-8, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24338457

RESUMEN

BACKGROUND AND AIM: Blood pressure is an independent predictor of target organ damage (TOD). Recent data from literature suggest that TOD can be present also in pre-hypertensive subjects, diagnosed with pressure monitoring (PM). Aim of this study is to clarify whether an augmentation of the carotid Intima-Media Thickness (cIMT) in office prehypertensives is a TOD associated to monitoring prehypertension (MP). PATIENTS AND METHODS: We have analyzed our database of individuals  office normotensives showing an increase of cIMT. The ambulatory blood pressure monitoring (ABPM) of these was compared with those of office monitoring normotensives, matched by age and gender, antropometric characteristics, negative for familial hypertension and other risk factors (true normotensives, TN). RESULTS: We have selected 15 presumable prehypetensives (PP) and 8 TN subjects. The ABPM (ambulatory blood pressure monitoring) analysis confirmed that neither the PP nor TN showed systolic (S) and diastolic (D) BP within-day values above their day-night upper reference limits. However the statistical comparison between PP and TN revealed that the first group had a significant elevation of SBP and DBP Daily Mean Level (DML(SBP/DBP): 121 ± 2/81 ± 2 vs 112 ± 2/70 ± 2 mmHg, respectively, p = 0.007 and p = 0.002), confirming the MP diagnosis. CONCLUSIONS: These results demonstrate that cIMT increase in PP fulfill the criteria for MP diagnosis, suggesting that MP should be undertaken in all PP with altered cIMT, but larger prospective studies are needed.


Asunto(s)
Presión Arterial , Determinación de la Presión Sanguínea , Enfermedades de las Arterias Carótidas/diagnóstico por imagen , Arteria Carótida Común/diagnóstico por imagen , Grosor Intima-Media Carotídeo , Visita a Consultorio Médico , Prehipertensión/diagnóstico , Adulto , Determinación de la Presión Sanguínea/métodos , Monitoreo Ambulatorio de la Presión Arterial , Distribución de Chi-Cuadrado , Femenino , Humanos , Masculino , Valor Predictivo de las Pruebas , Prehipertensión/fisiopatología , Estudios Retrospectivos
12.
Med Lav ; 104(2): 126-40, 2013.
Artículo en Italiano | MEDLINE | ID: mdl-23789519

RESUMEN

BACKGROUND: The Basilicata Regional Headquarters of the Italian Institute for Insurance against Occupational Accidents and Disease (INAIL) and the Basilicata association of small building enterprises (Edilcassa di Basilicata) promoted a research project to assess the risk of manual lifting and manual transport in construction enterprises in the Basilicata Region and estimate the prevalence of related diseases. METHODS: Manual lifting risk assessment was performed by calculating the VLI of 204 working days in as many building workers. Manual transport risk assessment was carried out comparing the weights transported (on the 204 days tested) with the reference values of the "Snoock and Ciriello" tables. RESULTS: Manual Ifting risk was present on 195 of the 204 days, with an average value of VLI equal to 2.1 (min 0.4, max 8.5), with higher values in the restructuring sector (VLI average of 2.3, min 0.4, max 8.5), and no significant differences between the different tasks. Manual transport risk was present on 129 of the 204 days, with average values of 1.2 (min 0.2, max 3.3), with no significant differences between the different tasks analyzed For both risks additional factors were present that were not analyzed by the methods of assessment used (for manual lifting: 8.8% of the geometries in the critical area; for manual transport: 39% of transport on shoulders, 42.5% on a route with uneven surface and 31.9% on a sloping route), so it is likely that the actual risk is greater than that indicated by the synthetic indices of exposure. The medical questionnaire showed from the case histories that 148 out of 546 subjects were positive for the threshold forpain or discomfort in the lumbosacral spine area and 99 out of 546 subjects reported suffering from an already diagnosed herniated spinal disk. Only 18% of osteoarticular diseases was reported to the Insurance Institute, al though there was widespread awareness that the diseases in question might be related to work. Diseases of the spine were responsible for 1.9% of absenteeism, equal to 30-40% of total absenteeism ofworkers enrolled in "Edilcassa di Basilicata". CONCLUSIONS: The method used provides a solid basis for evaluating the two risks in the construction industry, where employment is subject to extreme organizational, environmental and structural (machines, tools, operators involved) variability. Employment in the construction industry involves significant exposure to the two risks, counting for 30-40% of total absenteeism in this sector.


Asunto(s)
Materiales de Construcción , Elevación/efectos adversos , Enfermedades Musculoesqueléticas/epidemiología , Enfermedades Profesionales/epidemiología , Traumatismos Ocupacionales/epidemiología , Soporte de Peso , Absentismo , Accidentes de Trabajo/estadística & datos numéricos , Adulto , Algoritmos , Trastornos de Traumas Acumulados/epidemiología , Trastornos de Traumas Acumulados/etiología , Humanos , Desplazamiento del Disco Intervertebral/epidemiología , Desplazamiento del Disco Intervertebral/etiología , Italia/epidemiología , Dolor de la Región Lumbar/epidemiología , Dolor de la Región Lumbar/etiología , Persona de Mediana Edad , Enfermedades Musculoesqueléticas/etiología , Dolor de Cuello/epidemiología , Dolor de Cuello/etiología , Enfermedades Profesionales/etiología , Traumatismos Ocupacionales/etiología , Prevalencia , Medición de Riesgo , Encuestas y Cuestionarios
13.
Mediterr J Hematol Infect Dis ; 15(1): e2023064, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38028397

RESUMEN

Therapy-related Myeloid Neoplasm (t-MN) represents one of the worst long-term consequences of cytotoxic therapy for primary tumors and autoimmune disease. Poor survival and refractoriness to current treatment strategies characterize affected patients from a clinical point of view. In our aging societies, where newer therapies and ameliorated cancer management protocols are improving the life expectancy of cancer patients, therapy-related Myeloid Neoplasms are an emerging problem. Although several research groups have contributed to characterizing the main risk factors in t-MN development, the multiplicity of primary tumors, in association with the different therapeutic strategies available and the new drugs in development, make interpreting the current data still complex. The main risk factors involved in t-MN pathogenesis can be subgrouped into patient-specific, inherited, and acquired predispositions. Although t-MN can occur at any age, the risk tends to increase with advancing age, and older patients, characterized by a higher number of comorbidities, are more likely to develop the disease. Thanks to the availability of deep sequencing techniques, germline variants have been reported in 15-20% of t-MN patients, highlighting their role in cancer predisposition. It is becoming increasingly evident that t-MN with driver gene mutations may arise in the background of Clonal Hematopoiesis of Indeterminate Potential (CHIP) under the positive selective pressure of chemo and/or radiation therapies. Although CHIP is generally considered benign, it has been associated with an increased risk of t-MN. In this context, the phenomenon of clonal evolution may be described as a dynamic process of expansion of preexisting clones, with or without acquisition of additional genetic alterations, that, by favoring the proliferation of more aggressive and/or resistant clones, may play a crucial role in the progression from preleukemic states to t-MN.

14.
Eur Rev Med Pharmacol Sci ; 27(6 Suppl): 57-63, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-38112948

RESUMEN

OBJECTIVE: Autoimmune retinopathies (ARs) encompass a spectrum of immune diseases that are characterized by the presence of autoantibodies against retinal proteins in the bloodstream. These autoantibodies (AAbs) lead to a progressive and sometimes rapid loss of vision. ARs commonly affect subjects over 50 years of age, but also rare cases of kids under 3 years of age have been reported. PATIENTS AND METHODS: In this study, 47 unrelated Caucasian patients were enrolled. All subjects showed negative cancer diagnoses and negative results in their genetic screenings. We studied 8 confirmed retinal antigens using Western blotting analysis, with α-enolase followed by carbonic anhydrase II being the two most frequently found in the patients' sera. RESULTS: Nineteen patients were positive (40.4%), thirteen uncertain (27.7%), and fifteen were negative (31.9%). Their gender did not correlate with the presence of AAbs (p=0.409). CONCLUSIONS: AAbs are responsible for retinal degeneration in some cases, while in others, they contribute to exacerbating the progression of the disease; however, their detection is crucial to reaching a better diagnosis and developing more effective treatments for these conditions. Moreover, finding good biomarkers is important not only for AR monitoring and prognosis, but also for helping with early cancer diagnosis.


Asunto(s)
Enfermedades Autoinmunes , Neoplasias , Enfermedades de la Retina , Humanos , Persona de Mediana Edad , Autoanticuerpos , Autoantígenos , Enfermedades Autoinmunes/diagnóstico , Enfermedades de la Retina/diagnóstico
15.
G Ital Med Lav Ergon ; 34(3 Suppl): 466-8, 2012.
Artículo en Italiano | MEDLINE | ID: mdl-23405691

RESUMEN

Starting from different institutional tasks, occupational health physicians and National Health Services physicians have a common goal represented by workers' health protection. The comparison between these professionals should not be limited to the moment of surveillance but should seek opportunities for dialogue aimed at improving their quality of performance. The points of contact may be sought on issues such risk assessment, health protocol, occupational diseases, occupational epidemiology, information/training and health promotion.


Asunto(s)
Programas Nacionales de Salud/normas , Medicina del Trabajo/normas , Calidad de la Atención de Salud , Objetivos , Humanos , Italia , Médicos Laborales , Médicos
16.
Ann Oncol ; 22(7): 1628-1635, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21252060

RESUMEN

BACKGROUND: Epidemiological and clinical information on primary plasma cell leukemia (pPCL) are rarely reported. The aims are to evaluate the clinical features, prognostic factors, and efficacy of treatments in pPCL. PATIENTS AND METHODS: A multicenter retrospective cohort study was carried out from January 2000 to December 2008 in 26 Italian hematology divisions. A total of 128 cases of plasma cell leukemia were collected, and 73 of them (57%) were classified as primary (male/female 43/30). RESULTS: Sixty-four patients had at least 1 sign of end-organ damage and 10 had extramedullary localization. One patient died early; of the remaining patients, 36 (50%) received anthracycline-based regimens as first-line therapy, 17 (24%) single alkylating agents, and 30 (42%) bortezomib or thalidomide as additional (n = 11) or unique treatments (n = 19). Twenty-three patients (31%) underwent autologous and/or allogeneic hematopoietic stem cell transplantation (HSCT). The median overall survival (OS) was 12.6 months; complete or partial response was achieved in 22 (30%) and 18 patients (25%), respectively; the median duration of response (DOR) was 16.4 months. HSCT patients had a longer OS and DOR (median 38.1 and 25.8 months, respectively) compared with nontransplanted patients (9.1 and 7.3 months, respectively, P < 0.001). OS was influenced by nonresponse to treatment, hypoalbuminemia, and HSCT. DOR was favorably influenced only by HSCT. CONCLUSIONS: pPCL is an aggressive disease with a poor prognosis and a low response rate to conventional therapy. HSCT is effective, increasing OS and DOR by 69% and 88%, respectively. The use of bortezomib and thalidomide may improve outcomes.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Leucemia de Células Plasmáticas/terapia , Recurrencia Local de Neoplasia/terapia , Adulto , Anciano , Anciano de 80 o más Años , Antraciclinas/administración & dosificación , Ácidos Borónicos/administración & dosificación , Bortezomib , Estudios de Cohortes , Terapia Combinada , Femenino , Estudios de Seguimiento , Trasplante de Células Madre Hematopoyéticas , Humanos , Masculino , Persona de Mediana Edad , Pirazinas/administración & dosificación , Estudios Retrospectivos , Tasa de Supervivencia , Talidomida/administración & dosificación , Trasplante Autólogo , Resultado del Tratamiento , Adulto Joven
17.
Virol J ; 8: 22, 2011 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-21241513

RESUMEN

Many RNA viruses are displaying great promise in the field of oncolytic virotherapy. Previously, we reported that the picornavirus Coxsackievirus A21 (CVA21) possessed potent oncolytic activity against cultured malignant melanoma cells and melanoma xenografts in mice. In the present study, we demonstrate that three additional Group A Coxsackieviruses; Coxsackievirus A13 (CVA13), Coxsackievirus A15 (CVA15) and Coxsackievirus A18 (CVA18), also have similar oncolytic activity against malignant melanoma. Each of the viruses grew quickly to high titers in cancer cells expressing ICAM-1 and intratumoral injection of preformed subcutaneous SK-Mel-28 xenografts in mice with CVA13, CVA15 and CVA18 resulted in significant tumor volume reduction.As preexisting immunity could potentially hinder oncolytic virotherapy, sera from stage IV melanoma patients and normal controls were tested for levels of protective antibody against the panel of oncolytic Coxsackieviruses. Serum neutralization assays revealed that 3 of 21 subjects possessed low levels of anti-CVA21 antibodies, while protective antibodies for CVA13, CVA15 and CVA18 were not detected in any sample. Serum from individuals who were seropositive for CVA21 failed to exhibit cross-neutralization of CVA13, CVA15 and CVA18. From these studies it can be concluded that the administration of CVA13, CVA15 or CVA18 could be employed as a potential multivalent oncolytic therapy against malignant melanoma.


Asunto(s)
Enterovirus Humano A/crecimiento & desarrollo , Melanoma/terapia , Melanoma/virología , Viroterapia Oncolítica/métodos , Virus Oncolíticos/crecimiento & desarrollo , Animales , Anticuerpos Neutralizantes/sangre , Anticuerpos Antivirales/sangre , Línea Celular Tumoral , Modelos Animales de Enfermedad , Humanos , Melanoma/patología , Ratones , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/terapia , Neoplasias Cutáneas/virología , Trasplante Heterólogo/patología , Resultado del Tratamiento , Carga Viral
18.
Med Lav ; 102(1): 6-28, 2011.
Artículo en Italiano | MEDLINE | ID: mdl-21485483

RESUMEN

BACKGROUND AND OBJECTIVES: During the last Congress of the International Ergonomics Association (IEA), Beijing, August 2009, an international group was founded with the task of developing a "toolkit for MSD prevention" under the IEA and in collaboration with the World Health Organization. The possible users of toolkits are: members of health and safety committees; health and safety representatives; line supervisors; foremen; workers; government representatives; health workers providing basic occupational health services; occupational health and safety specialists. METHODS: According to the ISO standard 11228 series and the new Draft CD ISO 12259-2009: Application document guides for the potential user, our group developed a preliminary "mapping" methodology of occupational hazards in the craft industry, supported by software (Excel). RESULTS AND CONCLUSION: The proposed methodology, using specific key enters and quick assessment criteria, allows a simple ergonomics hazards identification and risk estimation to be made. It is thus possible to decide for which occupational hazards a more exhaustive risk assessment will be necessary and which occupational consultant should be involved (occupational physician, safety engineer, industrial hygienist, etc.).


Asunto(s)
Exposición Profesional/efectos adversos , Medición de Riesgo/métodos , Programas Informáticos , Fenómenos Biomecánicos , Ergonomía , Humanos
19.
Med Lav ; 102(1): 43-53, 2011.
Artículo en Italiano | MEDLINE | ID: mdl-21485485

RESUMEN

BACKGROUND: In 2006 there were more than 10,000 people working in artistic ceramics industries in Italy. The jobs in these industries that attracted most attention were work at the potter's wheel and decorating. OBJECTIVES: To test the premapping of risks data sheet in these enterprises. METHODS: We tested the data sheet in 3 craft industries: one was mainly artistic, one had a semi-industrial setting and in the third jobs were non-specific. RESULTS: In the semi-industrial craft industry the risks for potter's wheel workers were higher due to the repetitive movements required and to work organization aimed at achieving maximum productivity. CONCLUSIONS: The premapping of risks data sheet is a very sensitive tool. It can sometimes overestimate the risks, but in this way identifies situations that call for more in-depth analysis using tools that comply with international standards.


Asunto(s)
Arte , Cerámica , Industrias , Exposición Profesional/efectos adversos , Medición de Riesgo/métodos , Humanos , Industrias/métodos , Italia , Enfermedades Profesionales/epidemiología
20.
G Ital Dermatol Venereol ; 146(3): 179-83, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21566547

RESUMEN

AIM: Severe dry skin is very often associated with chronic skin conditions such as psoriasis vulgaris and can be treated with emollients and moisturizers. The aim of this study was to evaluate the efficacy and tolerability of a new cream containing glycerol, vaseline, and liquid paraffin versus an ointment containing vaseline in patients with severe dry skin and undergoing narrow band UVB phototherapy for moderate psoriasis vulgaris. METHODS: 54 patients were included in this study (age range, 18-63 years): 26 were randomized to receive treatment with the skin protection cream twice a day; 28 received treatment with a vaseline ointment twice a day. Clinical parameters (erythema, desquamation, and lichenification) were assessed at 3 time points (baseline, after two weeks of treatment, and at the end of the four-week study period). Treatment efficacy and tolerability were assessed by comparing changes in skin hydration as measured by corneometry. RESULTS: At the final assessment, greater improvement in clinical parameters and self-reported questionnaire responses was observed in the cream-treated than in the vaseline-treated group. Improved skin hydration was noted in the cream-treated group already after one week into therapy and the product was well tolerated. CONCLUSION: The new formulation cream was found to be effective in reducing eythema, flaking and lichenification and to improve skin hydration in patients undergoing narrow band UVB phototherapy for psoriasis vulgaris.


Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Glicerol/administración & dosificación , Aceite Mineral/administración & dosificación , Vaselina/administración & dosificación , Psoriasis/tratamiento farmacológico , Psoriasis/radioterapia , Terapia Ultravioleta , Administración Cutánea , Adulto , Método Doble Ciego , Combinación de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pomadas , Encuestas y Cuestionarios , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA